This document lists 48 original publications by JC Möller and collaborators related to Parkinson's disease, multiple system atrophy, restless legs syndrome, and other movement disorders. The publications cover a range of topics including experimental pain sensitivity, clinical decision making tools for chronic pain patients, roles of cortical and pallidal brain frequencies, association between sleep and dyskinesia in an animal model of Parkinson's, and several genetic studies related to various movement disorders.

1. Original publications
1. Mylius V, Pee S, Pape H, Teepker M, Stamelou M, Eggert K, Lefaucheur JP, Oertel WH, Möller JC:
Experimental pain sensitivity in multiple system atrophy and Parkinson`s disease at an early stage. Eur
J Pain, in press.
2. Zanini C, Maino P, Möller JC, Gobbi C, Raimondi M, Rubinelli S: Enhancing clinical decisions about
care through a pre-consultation sheet that captures patients` views on their health conditions and
treatments: a qualitative study in the field of chronic pain. Patient Educ Couns 99, 747-753, 2016.
3. Salvadè A, D’Angelo V, Di Giovanni G, Tinkhauser G, Sancesario G, Städler C, Möller JC, Stefani A,
Kaelin-Lang A, Galati S: Distinct roles of cortical and pallidal β and γ frequencies in hemiparkinsonian
and dyskinetic rats. Exp Neurol 275:199-208, 2016.
4. Galati S, Salvadè A, Pace M, Sarasso S, Baracchi F, Bassetti CL, Kaelin-Lang A, Städler C, Stanzione
P, Möller JC: Evidence of an association between sleep and levodopa-induced dyskinesia in an animal
model of Parkinson’s disease. Neurobiol Aging 36:1577-1589, 2015.
5. Galati S, Städler C, Möller JC. Parkinsonism and Gorlin-Goltz syndrome, more than an incidental
association? J Neuropsychiatry Clin Neurosci 27:e83-84, 2015.
6. Galati S, Möller JC, Städler C: Ropinirole-induced Pisa syndrome in Parkinson’s disease. Clin
Neuropharmacol 37:58-59, 2014.
7. Prosperetti C, Di Giovanni G, Stefani A, Möller JC, Galati S: Acute nigro-striatal blockade alters
cortico-striatal encoding: an in vivo electrophysiological study. Exp Neurol 247:730-736, 2013.
8. Unger MM, Ekman R, Björklund AK, Karlsson G, Andersson C, Mankel K, Bohne K, Tebbe JJ, Stiasny-
Kolster K, Möller JC, Mayer G, Kann PH, Oertel WH: Unimpaired postprandial pancreatic polypeptide
secretion in Parkinson’s disease and REM sleep behavior disorder. Mov Disord 28:529-533, 2013.
9. Alvarez-Fischer D, Grundmann M, Lu L, Samans B, Fritsch B, Möller JC, Schäfer MK, Hartmann A,
Oertel WH, Bandmann O: Prolonged generalized dystonia after chronic cerebellar application of kainic
acid. Brain Res 1464:82-88, 2012.
10. Menzler K, Belke M, Unger MM, Ohletz T, Keil B, Heverhagen JT, Rosenow F, Mayer G, Oertel WH,
Möller JC, Knake S. DTI reveals hypothalamic and brainstem white matter lesions in patients with
idiopathic narcolepsy. Sleep Med 13:736-742, 2012.
11. Stamelou M, Dohmann H, Brebbermann J, Boura E, Oertel WH, Höglinger G, Möller JC, Mylius V:
Clinical pain and experimental pain sensitivity in progressive supranuclear palsy. Parkinsonism Rel
Disord 18:606-608, 2012.
12. Unger MM, Möller JC, Mankel K, Eggert KM, Stamelou M, Stiasny-Kolster K, Bohne K, Bodden M,
Mayer G, Oertel WH, Tebbe JJ: Patients with idiopathic rapid-eye movement sleep disorder show normal
gastric motility assessed by the 13
C-octanoate breath test. Mov Disord 26:2559-2563, 2011.
13. Kauther KM, Höft C, Rissling I, Oertel WH, Möller JC: Mutations in the PLA2G6 gene in patients with
early-onset Parkinson’s disease. Mov Disord 26:2415-2417, 2011.
14. Mylius V, Brebbermann J, Engau I, Oertel WH, Möller JC: Pain sensitivity and clinical progression in
Parkinson’s disease. Mov Disord 26:2220-2225, 2011.
15. Unger MM, Möller JC, Mankel K, Eggert KM, Bohne K, Bodden M, Stiasny-Kolster K, Kann PH,
Mayer G, Tebbe JJ, Oertel WH. Postprandial ghrelin response is reduced in patients with Parkinson’s
disease and idiopathic REM sleep behaviour disorder. A peripheral biomarker for early Parkinson’s
disease? J Neurol 258:982-990. 2011.

2. 16. Buob A, Winter H, Kindermann M, Becker G, Möller JC, Oertel WH, Böhm M. Parasympathetic but
not sympathetic cardiac dysfunction at early stages of Parkinson’s disease. Clin Res Cardiol 99:701-
706, 2010.
17. Hölscher S, Leinweber B, Hefter H, Reuner U, Günther P, Weiss KH, Oertel WH, Möller JC:
Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson Disease. Eur
Neurol 64:83-87, 2010.
18. Unger MM, Belke M, Menzler K, Heverhagen JT, Keil B, Stiasny-Kolster K, Rosenow F, Diederich NJ,
Mayer G, Möller JC, Oertel WH, Knake S. Diffusion tensor imaging in idiopathic REM sleep behavior
disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other
brain regions. Sleep 33:767-773, 2010.
19. Unger MM, Hattemer K, Möller JC, Schmittinger K, Mankel K, Eggert K, Strauch K, Tebbe JJ, Keil
B, Oertel WH, Heverhagen JT, Knake S: Real-time visualization of altered gastric motility by magnetic
resonance imaging in patients with Parkinson’s disease. Mov Disord 25:623-638, 2010.
20. Mylius V*, Möller JC*, Strauch K, Oertel WH, Stiasny-Kolster K: No significance of the COMT
val158
met polymorphism in restless legs syndrome. Neurosci Lett 473:151-154, 2010.
*Both authors contributed equally to this publication.
21. Unger MM, Möller JC, Ohletz T, Stiasny-Kolster K, Oertel WH, Mayer G: Transcranial midbrain
sonography in narcoleptic subjects with and without concomitant REM sleep behaviour disorder. J
Neurol 256:874-877, 2009.
22. Rissling I, Strauch K, Höft T, Oertel WH, Möller JC: Haplotype analysis of the engrailed-2 gene in
young-onset Parkinson’s disease. Neurodegener Dis 6:102-105, 2009.
23. Stiasny-Kolster K, Möller JC, Heinzel-Gutenbrunner M, Baum E, Ries V, Oertel WH: Diagnostic
accuracy of the RLS screening questionnaire (RLSSQ). Somnology 13:37-42, 2009.
24. Möller JC, Unger M, Stiasny-Kolster K, Kaussner Y, Penzel T, Oertel WH, Hemmeter U: Continuous
sleep EEG monitoring in PD patients with and without sleep attacks. Parkinsonism Rel Disord 15:238-
241, 2009.
25. Teepker M, von Brocke K, Mylius V, Haag A, Möller JC, Oertel WH, Schepelmann K: Serum
concentrations of S100b and NSE in migraine. Headache 49:245-252, 2009.
26. Mylius V, Engau I, Teepker M, Stiasny-Kolster K, Schepelmann K, Oertel WH, Lautenbacher S,
Möller JC: Pain sensitivity and descending inhibition of pain in Parkinson’s disease. J Neurol
Neurosurg Psychiatry 80:24-28, 2009.
27. Möller JC, Tackenberg B, Heinzel-Gutenbrunner M, Burmester R, Oertel WH, Bandmann O, Müller-
Vahl K: Immunophenotyping in Tourette syndrome - a pilot study. Eur J Neurol 15:749-753, 2008.
28. Möller JC, Rissling I, Mylius V, Höft T, Eggert KM, Oertel WH: The prevalence of the G2019S and
R1441C/G/H mutations in LRRK2 in German patients with Parkinson’s disease. Eur J Neurol 15:743-
745, 2008.
29. Bach JP, Sommer N, Möller JC, Oertel WH, Dodel R, Gasser T: Parkinson’s syndrome in a young
patient with Klinefelter’s syndrome - a case report. Mov Disord 23:771-772, 2008.
30. Paus S, Grünewald A, Klein C, Knapp M, Zimprich A, Janetzky B, Möller JC, Klockgether T,
Wüllner U: The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson’s
disease. Mov Disord 23:599-602, 2008.
31. Unger MM, Möller JC, Stiasny-Kolster K, Mankel K, Berg D, Walter U, Höffken H, Mayer G, Oertel
WH: Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial
sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 23:596-599, 2008.

3. 32. Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJG, Schmidt HHJ, Schrader C,
Bandmann O, Czlonkowska A, Oertel WH, Hefter H: Evaluation of the Unified Wilson’s Disease
Rating Scale (UWDRS) in German patients with treated Wilson’s disease. Mov Disord 23:54-62, 2008.
33. Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH: The REM
sleep behavior disorder screening questionnaire. Mov Disord 22:2386-2393, 2007.
34. Macht M, Kaussner Y, Möller JC, Stiasny-Kolster K, Eggert KM, Krüger HP, Ellgring H: Predictors
of freezing in Parkinson’s disease: a survey of 6620 patients. Mov Disord 22:953-956, 2007.
35. Tackenberg B, Metz A, Unger M, Schimke N, Passow S, Höffken H, Hoffmann GF, Müller U, Nolte
D, Oertel WH, Eggert K, Möller JC: Nigrostriatal dysfunction in X-linked dystonia-parkinsonism
(Lubag). Mov Disord 22:900-902, 2007.
36. Czlonkowska A, Tarnacka B, Möller JC, Leinweber B, Bandmann O, Woimant F, Oertel WH: Unified
Wilson’s Disease Rating Scale - a proposal for the neurological scoring of Wilson’s disease patients.
Neurol Neurochir Pol 41:1-12, 2007.
37. Walters SA, Elin RJ, Cohen B, Möller JC, Oertel W, Stiasny-Kolster K: Magnesium not likely to play
a major role in the pathophysiology of Restless Legs Syndrome: serum and cerebrospinal fluid studies.
Sleep Med 8:186-187, 2007.
38. Stiasny-Kolster K, Clever SC, Möller JC, Oertel WH, Mayer G: Olfactory dysfunction in patients with
narcolepsy with and without REM sleep behavior disorder. Brain 130:442-449, 2007.
39. Tackenberg B, Möller JC, Rindock H, Bien S, Sommer N, Oertel WH, Rosenow F, Schepelmann K,
Hamer HM, Bandmann O: Central nervous system involvement in hereditary neuropathy with pressure
palsies (HNPP). Neurology 67:2250-2252, 2006.
40. Möller JC, Leinweber B, Rissling I, Oertel WH, Bandmann O, Schmidt HH: The prevalence of the
H1069Q mutation in ATP7B in discordant pairs with early-onset Parkinson’s disease. Mov Disord
21:1789-1790, 2006.
41. Stiasny-Kolster K, Kohnen R, Möller JC, Trenkwalder C, Oertel WH: Validation of the „L-Dopa test“
for diagnosis of restless legs syndrome. Mov Disord 21:1333-1339, 2006.
42. Möller JC, Körner Y, Cassel W, Meindorfner C, Krüger HP, Oertel WH, Stiasny-Kolster K: Sudden
onset of sleep and dopaminergic therapy in patients with restless legs syndrome. Sleep Med 7:333-339,
2006.
43. Möller JC, Krüttgen A, Burmester R, Weis J, Oertel WH, Shooter EM: Release of interleukin-6 via the
regulated secretory pathway in PC12 cells. Neurosci Lett 400:75-79, 2006.
44. Ozawa T, Healy DG, Abou-Sleiman PM, Ahmadi KR, Quinn N, Lees AJ, Shaw K, Wüllner U,
Berciano J, Möller JC, Kamm C, Bürk K, Josephs KA, Barone P, Tolosa E, Goldstein DB, Wenning
G, Geser F, Holton JL, Gasser T, Revesz T, Wood NW, the European MSA study group: The alpha-
synuclein gene in multiple system atrophy. J Neurol Neurosurg Psychiatry 77:464-467, 2006.
45. Tackenberg B, Möller JC, Eggert K, Sommer N, Oertel WH: Akinetic crisis caused by rectus sheath
hematoma and acute anemia due to subcutaneous administration of apomorphine. Mov Disord 21:126-
127, 2006.
46. Rissling I, Frauscher B, Kronenberg F, Tafti M, Stiasny-Kolster K, Robyr AC, Körner Y, Oertel WH,
Poewe W, Högl B, Möller JC: Daytime sleepiness and the COMT val158met polymorphism in
patients with Parkinson disease. Sleep 29:108-111, 2006.
47. Möller JC, Rethfeldt M, Körner Y, Stiasny-Kolster K, Cassel W, Meindorfner C, Rissling I, Krüger
HP, Oertel WH: Daytime sleep latency in medication-matched PD patients with and without sudden
onset of sleep. Mov Disord 20:1620-1622, 2005.

4. 48. Berg D, Niwar M, Maass S, Zimprich A, Möller JC, Wüllner U, Schmitz-Hübsch T, Klein C, Tan EK,
Schöls L, Marsh L, Dawson TM, Janetzky B, Müller T, Woitalla D, Kostic V, Pramstaller PP, Oertel
WH, Bauer P, Krüger R, Gasser T, Riess O: Alpha-synuclein and Parkinson’s disease: implications
from the screening of more than 1900 patients. Mov Disord 20:1191-1194, 2005.
49. Kamm C, Healy DG, Quinn NP, Wüllner U, Möller JC, Schoels L, Geser F, Bürk K, Boerglum A,
Pellecchia MT, Tolosa E, del Sorbo F, Nilsson C, Bandmann O, Sharma M, Mayer P, Gasteiger M,
Haworth A, Ozawa T, Lees AJ, Holinski-Feder E, Illig T, Wichmann E, Wenning GK, Wood NW,
Gasser T for the European Multiple System Atrophy (EMSA) Study Group: The fragile X tremor
ataxia syndrome in the differential diagnosis of MSA: data from the EMSA study group. Brain
128:1855-1860, 2005.
50. Möller JC, Cassel W, Stiasny-Kolster K, Jerrentrup A, Körner Y, Krüger HP, Becker H, Oertel WH:
“Sleep attacks” in patients with sleep-disordered breathing. Somnology 9:127-132, 2005.
51. Möller JC, Körner Y, Dodel RC, Meindorfner C, Stiasny-Kolster K, Spottke A, Krüger HP, Oertel
WH: Pharmacotherapy of Parkinson’s disease in Germany. J Neurol 252:926-935, 2005.
52. Rissling I, Körner Y, Geller F, Stiasny-Kolster K, Oertel WH, Möller JC: Preprohypocretin
polymorphisms in Parkinson’s disease reporting “sleep attacks”. Sleep 28:871-875, 2005.
53. Meindorfner C, Körner Y, Möller JC, Stiasny-Kolster K, Oertel WH, Krüger HP: Driving in
Parkinson’s disease - mobility, accidents and SOS at the wheel. Mov Disord 20:832-842, 2005.
54. Möller JC, Oertel WH, Köster J, Pezzoli G, Provinciali L: Long-term efficacy and safety of
pramipexole in advanced Parkinson’s disease: results from a European multicenter trial. Mov Disord
20:602-610, 2005.
55. Stiasny-Kolster K, Dörr Y, Möller JC, Höffken, H, Behr TM, Oertel WH, Mayer GM: Combination of
idiopathic REM sleep behavior disorder and olfactory dysfunction as possible indicator for -
synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126-137, 2005.
56. Stiasny-Kolster K, Kohnen R, Schollmayer E, Möller JC, Oertel WH, The Rotigotine SP666 Study
Group: Patch application of the dopamine agonist rotigotine to patients with moderate to advanced
stages of restless legs syndrome: A double-blind placebo-controlled pilot study. Mov Disord 19:1432-
1438, 2004.
57. Körner Y, Meindorfner C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger HP:
Predictors of sudden onset of sleep in Parkinson’s disease. Mov Disord 19:1298-1305, 2004.
58. Rissling I, Geller F, Bandmann O, Stiasny-Kolster K, Körner Y, Meindorfner C, Oertel WH, Möller
JC: Dopamine receptor gene polymorphisms in PD patients reporting „sleep attacks“. Mov Disord
19:1279-1284, 2004.
59. Heiser P, Teepker M, Möller JC, Theisen FM, Friedel S, Hebebrand J, Remschmidt H: Neuropathy
due to hypovitaminosis following excessive weight loss. J Am Acad Child Psychiatry 43:928-929,
2004.
60. Möller JC, Depboylu C, Kölsch H, Lohmüller F, Bandmann O, Gocke P, Du Y, Paus M, Wüllner U,
Gasser T, Oertel WH, Klockgether T, Dodel RC: Lack of association between the IL-1 alpha (-889)
polymorphism and early-onset Parkinson’s disease. Neurosci Lett 359:195-197, 2004.
61. Stiasny-Kolster K, Magerl W, Oertel WH, Möller JC, Treede RD: Static mechanical hyperalgesia
without dynamic tactile allodynia in patients with restless legs syndrome. Brain 127:773-782, 2004.
62. Wu YJ, Krüttgen A, Möller JC, Shine D, Chan JR, Shooter EM, Cosgaya JM: Nerve growth factor,
brain-derived neurotrophic factor, and neurotrophin-3 are sorted to dense-core vesicles and released via
the regulated pathway in primary rat cortical neurons. J Neurosci Res 75, 825-834, 2004.

5. 63. Healy DG, Abou-Sleiman PM, Ozawa T, Lees AJ, Bhatia K, Ahmadi KR, Wüllner U, Berciano J,
Möller JC, Kamm C, Burk K, Barrone P, Tolosa E, Quinn N, Goldstein DB, Wood NW. A functional
polymorphism regulating dopamine beta-hydroxylase influences against Parkinson’s disease. Ann
Neurol 55:443-446, 2004.
64. Stiasny-Kolster K, Möller JC, Zschocke J, Bandmann O, Cassel W, Oertel WH, Hoffmann GF:
Normal dopaminergic and serotonergic metabolites in CSF and blood of restless legs syndrome
patients. Mov Disord 19, 192-196, 2004.
65. Möller JC, Sünkeler IH, Oertel WH, Mennel HD: Pigmentary orthochromatic leukodystrophy.
Nervenarzt 74:1127-1133, 2003.
66. Stiasny-Kolster K, Mignot E, Ling L, Möller JC, Cassel W, Oertel WH: CSF hypocretin-1 levels in
restless legs syndrome. Neurology 61:1426-1429, 2003.
67. Dodel RC, Höffken H, Möller JC, Bornschein B, Behr T, Oertel WH, Siebert U: Dopamine transporter
imaging and SPECT in diagnostic work-up of Parkinson’s disease: a decision-analytic approach. Mov
Disord Suppl 7:S52-62, 2003.
68. Oertel WH, Gerstner A, Höffken H, Dodel RC, Eggert K, Möller JC: Role of dopamine transporter
SPECT for the practitioner and the general neurologist. Mov Disord Suppl 7:S9-15, 2003.
69. Körner Y, Meindorfner C, Möller JC, Stiasny-Kolster K, Haja D, Cassel W, Oertel WH, Krüger HP:
Correlation of self-reported daytime sleepiness and self-reported sleep disorders before and after the
onset of Parkinson’s disease (PD) - data from a questionnaire survey with 6620 PD patients.
Somnology 7:79-88, 2003.
70. Möller JC, Stiasny K, Hargutt V, Cassel W, Tietze H, Peter JH, Krüger HP, Oertel WH: Evaluation of
sleep and driving performance in six patients with Parkinson's disease reporting sudden onset of sleep
under dopaminergic medication - a pilot study. Mov Disord 17:474-481, 2002.
71. Möller JC, Hamer HM, Oertel WH, Rosenow F: Late-Onset Myoclonic Epilepsy in Down’s Syndrome
(LOMEDS). 1) Seizure 10:303-306, 2001 and 2) Seizure Suppl A:303-305, 2002.
72. Kalla R, Liu Z, Xu S, Koppius A, Imai Y, Kloss CU, Kohsaka S, Gschwendtner A, Möller JC, Werner
A, Raivich G: Microglia and the early phase of immune surveillance in the axotomized facial motor
nucleus: Impaired microglial activation and lymphocyte recruitment but no effect on neuronal survival
or axonal regeneration in MCSF-deficient mice. J Comp Neurol 436:182-201, 2001.
73. Stiasny K, Möller JC, Oertel WH: Safety of pramipexole in patients with restless legs syndrome.
Neurology 55:1589-1590, 2000.
74. Künig G, Pogarell O, Möller JC, Delf M, Oertel WH: Pramipexole, a non-ergot dopamine agonist, is
effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin Neuropharmacol
22:301-305, 1999.
75. Klein RL, King MA, Muir DF, Peel AL, Zolotukhin S, Möller JC, Krüttgen A, Heymach JV,
Muzyczka N, Meyer EM: Long-term actions of vector-derived NGF or BDNF on choline
acetyltransferase and Trk receptor levels in the adult rat basal forebrain. Neuroscience 90:815-821,
1999.
76. Krüttgen A*, Möller JC*, Heymach JV, Shooter EM: Neurotrophins induce release of neurotrophins
by the regulated secretory pathway. Proc Natl Acad Sci USA 95:9614-9619, 1998.
*Both authors contributed equally to this publication.
77. Möller JC*, Krüttgen A*, Heymach JV, Ghori N, Shooter EM: Subcellular localization of epitope-
tagged neurotrophins in neuroendocrine cells. J Neurosci Res 51:463-472, 1998.
*Both authors contributed equally to this publication.

6. 78. Klein MA*, Möller JC*, Jones LL, Bluethmann H, Kreutzberg GW, Raivich G: Impaired neuroglial
activation in interleukin-6 deficient mice. Glia 19:227-233, 1997.
*Both authors contributed equally to this publication.
79. Möller JC, Klein MA, Haas S, Jones LL, Kreutzberg GW, Raivich G: Regulation of thrombospondin
in the regenerating mouse facial motor nucleus. Glia 17:121-132, 1996.
80. Raivich G, Moreno-Flores MT, Möller JC, Kreutzberg GW: Inhibition of microglial proliferation in a
genetic model of macrophage colony stimulating factor deficiency. Eur J Neurosci 6:1615-1618, 1994.
81. Lütticken C, Krüttgen A, Möller C, Heinrich PC, Rose-John S: Evidence for the importance of a
positive charge and an -helical structure of the c-terminus of human interleukin-6; evidence for the
involvement of the carboxy-terminus in function. FEBS Lett 262:323-326, 1990.
82. Krüttgen A, Rose-John S, Möller C, Wroblowski B, Wollmer A, Müllberg J, Hirano T, Kishimoto T,
Heinrich PC: Structure-function analysis of human interleukin-6; evidence for the involvement of the
carboxy-terminus in function. FEBS Lett 262:323-326, 1990.
Group authorships
83. Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Landwehrmeyer BG, van der Mast RC,
Giltay EJ, REGISTRY investigators of the European Huntington’s Disease Network. J Affect Disord
151:248-58, 2013.
84. Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D, REGISTRY Investigators of the
European Huntington’s Disease Network, Nguyen HP. The V471A polymorphism in autophagy-
related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients. PLoS One
8:e68951, 2013.
85. Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross
CA, Margolis RL, Squitieri F, Orobello S, di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O,
Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH,
Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J,
Paulsen JS, Predict-HD study of the Huntington Study Group, Landwehrmeyer GB, REGISTRY study
of the European Huntington`s Disease Network, Myers RH, HD-MAPS study group, MacDonald ME,
Gusella JF, COHORT study of the HSG. CAG repeat expansion in Huntington disease determines age
at onset in a fully dominant fashion. Neurology 78:690-695, 2012.
86. Quarrell OW, Handley O, O’Donovan K, Dumoulin K, Ramos-Arroyo M, Biunno I, Bauer P, Kline M,
Landwehrmeyer GB, European Huntington’s Disease Network. Discrepancies in reporting the CAG
repeat lengths for Huntington’s disease. Eur J Hum Genet 20:20-26, 2012.
87. Orth M, European Huntington’s Disease Network. Observing Huntington’s disease: the European
Huntington’s Disease Network’s REGISTRY. J Neurol Neurosurg Psychiatry 82:1409-1412, 2011.
88. Höglinger GU, Melham NM, Dickson DW, Sleiman PMA, Wang LS, Klei L, Rademakers R, de Silva
R, Litvan I, Riley DE, van Swieten JC, Heutink P, Wszolek ZK, Uitti RJ, Vandrovcova J, Hurtig HI,
Gross RG, Maetzler W, Goldwurm S, Tolosa E, Borroni B, Pastor P, PSP Genetics Study Group,
Cantwell LB, Han MR, Dillman A, van der Brug MP, Gibbs JR, Cookson MR, Hernandez DG, Singleton
AB, Farrer MJ, Yu CE, Golbe LI, Revesz T, Hardy J, Lees AJ, Devlin B, Hakonarson H, Müller U,
Schellenberg GD. Identification of common variants influencing risk of the tauopathy progressive
supranuclear palsy. Nat Genet 43:699-705, 2011.
89. Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T,
Mylylla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi
B, Chaudhuri KR, RECOVER study group: Rotigotine effects on early morning motor function and

7. sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov
Disord 26:90-99, 2011.
90. Orth M, Handley OJ, Schwenke C, Dunnett SB, Crauford D, Ho AK, Wild E, Tabrizi SJ, Landwehrmeyer
GB, Investigators of the European Huntington's Disease Network. Observing Huntington's Disease:
the European Huntington's Disease Network's REGISTRY. PLoS Curr 2:RRN1184, 2010.
91. Aziz NA, Jurgens CK, Landwehrmeyer GB, EHDN Registry Study Group, van Roon-Mom WMC, van
Ommen GJB, Stijnen T, Roos RAC. Normal and mutant HTT interact to affect clinical severity and
progression in Huntington disease. Neurology 73:1280-1285, 2009.
92. Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Trenkwalder C, Tacken I, Schollmayer
E, Kohnen R, Stiasny-Kolster K, on behalf of the Rotigotine SP710 Study Group: One year open-
label safety and efficacy trial with rotigotine transdermal patch in moderate and severe idiopathic
restless legs syndrome. Sleep Med 9:865-873, 2008.
93. Oertel WH, Benes H, Garcia-Borreguero D, Geisler P, Högl B, Saletu B, Trenkwalder C, Sommerville
KW, Schollmayer E, Kohnen R, Stiasny-Kolster K, on behalf of the Rotigotine SP709 Study Group:
Efficacy of rotigotine transdermal system in severe restless legs syndrome: a randomized, double-blind,
placebo-controlled, six-week dose-finding trial in Europe. Sleep Med 9:228-239, 2008.